CLS Americas Announces Research Collaboration with the National Institutes of Health Clinical Center to Study MRI/Ultrasound Fusion-Guided FLA of Prostate Tissue and Prostate Cancer

Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced a research collaboration agreement between the National Institutes of Health Clinical Center (NIHCC) and its parent company, Clinical Laserthermia Systems AB, based in Sweden.  

Under the agreement, NIHCC will access the clinical utility of the CLS’s TRANBERG® Thermal Therapy System towards MRI/Ultrasound fusion-guided focal laser ablation (FLA) of prostate tissue and prostate cancer in male patients.

“CLS is honored to initiate this collaboration with the NIH to evaluate our TRANBERG laser system for image-guided, focal therapies to treat prostate cancer,” said Michael Magnani, President of CLS Americas. “We view this as a strategic relationship and share a common goal with the NIH to effectively treat prostate cancer while also preserving a high quality of life for the patient.”


Read the full press release here:


Welcome to Clinical Laserthermia Systems.

Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!

Please choose your country or region